Logo

Viela Bio's Uplizna (inebilizumab-cdon) Receives the US FDA's Approval to Treat Neuromyelitis Optica Spectrum Disorder (NMOSD)

Share this

Viela Bio's Uplizna (inebilizumab-cdon) Receives the US FDA's Approval to Treat Neuromyelitis Optica Spectrum Disorder (NMOSD)

Shots:

  • The approval is based on N-MOmentum trial which involves assessing of Uplizna (300mg) vs placebo in 213 patients in the ratio (3:1) at day 1 to day 15 who are anti-AQP4 antibody-positive/negative   
  • The study resulted in anti-AQP4 antibody-positive group remained relapse-free (89% vs 58%) including reductions in NMOSD-related hospitalizations with safety and tolerability profile
  • Uplizna (inebilizumab-cdon) is a humanized CD19-directed mAb and is a novel B cell depleter approved for the treatment of NMOSD in adults who are anti-aquaporin-4 (AQP4) antibody positive

Ref: Viela | Image: Signbox

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions